Parenteral antithrombotic therapy during primary percutaneous coronary intervention

Federico Fortuni, Marco Ferlini, Sergio Leonardi

Research output: Contribution to journalReview article

Abstract

Acute myocardial infarction (AMI) is a major cause of morbidity, mortality and disability worldwide. ST-segment elevation myocardial infarction (STEMI) accounts for 25-40% of AMI presentations. Arterial thrombosis due to atherosclerotic plaque rupture with formation of an occlusive thrombus is the main cause of STEMI. Platelets and coagulation factors are the two principal elements involved in this process. The main goal of STEMI treatment is the early reperfusion. Prompt primary percutaneous coronary intervention (pPCI) together with an appropriate antithrombotic therapy are the treatment of choice in this setting. In this chapter, we provide an overview of currently available parenteral antithrombotic therapies used in patients with STEMI undergoing pPCI.

Original languageEnglish
Pages (from-to)411-421
Number of pages11
JournalMinerva Cardioangiologica
Volume66
Issue number4
DOIs
Publication statusPublished - Aug 1 2018
Externally publishedYes

Fingerprint

Percutaneous Coronary Intervention
Myocardial Infarction
Thrombosis
Therapeutics
Blood Coagulation Factors
Atherosclerotic Plaques
Reperfusion
Rupture
Blood Platelets
Morbidity
Mortality

Keywords

  • Fibrinolytic agents
  • Infusions, parenteral
  • ST elevation myocardial infarction
  • Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Parenteral antithrombotic therapy during primary percutaneous coronary intervention. / Fortuni, Federico; Ferlini, Marco; Leonardi, Sergio.

In: Minerva Cardioangiologica, Vol. 66, No. 4, 01.08.2018, p. 411-421.

Research output: Contribution to journalReview article

@article{357f3a8b3ac5467194fd7ca1e95f0e2b,
title = "Parenteral antithrombotic therapy during primary percutaneous coronary intervention",
abstract = "Acute myocardial infarction (AMI) is a major cause of morbidity, mortality and disability worldwide. ST-segment elevation myocardial infarction (STEMI) accounts for 25-40{\%} of AMI presentations. Arterial thrombosis due to atherosclerotic plaque rupture with formation of an occlusive thrombus is the main cause of STEMI. Platelets and coagulation factors are the two principal elements involved in this process. The main goal of STEMI treatment is the early reperfusion. Prompt primary percutaneous coronary intervention (pPCI) together with an appropriate antithrombotic therapy are the treatment of choice in this setting. In this chapter, we provide an overview of currently available parenteral antithrombotic therapies used in patients with STEMI undergoing pPCI.",
keywords = "Fibrinolytic agents, Infusions, parenteral, ST elevation myocardial infarction, Therapeutics",
author = "Federico Fortuni and Marco Ferlini and Sergio Leonardi",
year = "2018",
month = "8",
day = "1",
doi = "10.23736/S0026-4725.18.04619-4",
language = "English",
volume = "66",
pages = "411--421",
journal = "Minerva Cardioangiologica",
issn = "0026-4725",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "4",

}

TY - JOUR

T1 - Parenteral antithrombotic therapy during primary percutaneous coronary intervention

AU - Fortuni, Federico

AU - Ferlini, Marco

AU - Leonardi, Sergio

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Acute myocardial infarction (AMI) is a major cause of morbidity, mortality and disability worldwide. ST-segment elevation myocardial infarction (STEMI) accounts for 25-40% of AMI presentations. Arterial thrombosis due to atherosclerotic plaque rupture with formation of an occlusive thrombus is the main cause of STEMI. Platelets and coagulation factors are the two principal elements involved in this process. The main goal of STEMI treatment is the early reperfusion. Prompt primary percutaneous coronary intervention (pPCI) together with an appropriate antithrombotic therapy are the treatment of choice in this setting. In this chapter, we provide an overview of currently available parenteral antithrombotic therapies used in patients with STEMI undergoing pPCI.

AB - Acute myocardial infarction (AMI) is a major cause of morbidity, mortality and disability worldwide. ST-segment elevation myocardial infarction (STEMI) accounts for 25-40% of AMI presentations. Arterial thrombosis due to atherosclerotic plaque rupture with formation of an occlusive thrombus is the main cause of STEMI. Platelets and coagulation factors are the two principal elements involved in this process. The main goal of STEMI treatment is the early reperfusion. Prompt primary percutaneous coronary intervention (pPCI) together with an appropriate antithrombotic therapy are the treatment of choice in this setting. In this chapter, we provide an overview of currently available parenteral antithrombotic therapies used in patients with STEMI undergoing pPCI.

KW - Fibrinolytic agents

KW - Infusions, parenteral

KW - ST elevation myocardial infarction

KW - Therapeutics

UR - http://www.scopus.com/inward/record.url?scp=85049670821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049670821&partnerID=8YFLogxK

U2 - 10.23736/S0026-4725.18.04619-4

DO - 10.23736/S0026-4725.18.04619-4

M3 - Review article

AN - SCOPUS:85049670821

VL - 66

SP - 411

EP - 421

JO - Minerva Cardioangiologica

JF - Minerva Cardioangiologica

SN - 0026-4725

IS - 4

ER -